Esperion Therapeutics Inc

Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The company leverages deep domain expertise in ATP-citrate lyase (ACLY) biology to develop transformative medicines. Esperion currently markets two oral, once-daily, non-statin therapies — NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid/ezetimibe combination) — for patients struggling to maintain LDL cholesterol levels who are at risk of cardiovascular disease. These products are indicated to reduce the risk of major adverse cardiovascular events in adults unable to take recommended statin therapy and as adjuncts to diet and exercise for reducing LDL-C in adults with hypercholesterolemia. With U.S. commercial infrastructure and global approvals across more than 40 countries through strategic partnerships with Daiichi Sankyo Europe, Otsuka Pharmaceutical in Japan, HLS Therapeutics in Canada, Neopharm in Israel, and CSL Seqirus in Australia and New Zealand, Esperion is expanding its global reach. The company is also advancing its pipeline, including ESP-2001 for primary sclerosing cholangitis and oral triple combination lipid-lowering therapies, and recently agreed to acquire Corstasis Therapeutics to add Enbumyst (bumetanide nasal spray) for edema associated with congestive heart failure. Updated Mar 10, 2026